How to Make Anthrax Vaccines That Survive Freezing

A method for protecting sensitive anthrax vaccines from damage during freezing and thawing by using specific sugars and additives during the drying process.

What it covers

This patent describes a way to stabilize anthrax vaccines so they do not lose their effectiveness when frozen or dried. The process involves taking an anthrax antigen attached to an aluminum adjuvant and swapping out the original liquid for a new mixture containing high concentrations of non-reducing sugars like trehalose or sucrose. By removing the original liquid through centrifugation or filtration and replacing it with this sugar-rich solution, the vaccine can be lyophilized (freeze-dried) without the proteins falling apart. This ensures the vaccine remains potent even after being stored in harsh conditions.

What it doesn't cover

• —Does not cover vaccines that do not use aluminum-based adjuvants.
• —Does not cover liquid-only vaccines that are not intended for lyophilization.
• —Does not cover the use of reducing sugars like glucose or fructose for stabilization.
• —Does not cover methods that do not involve the specific step of exchanging the liquid component.

The clever bit

The innovation lies in the specific liquid-exchange process that replaces the original buffer with a high-concentration non-reducing sugar solution, which acts as a molecular scaffold to prevent the antigen from denaturing during the stress of freeze-drying.

Why it matters

Vaccines are often delicate proteins that degrade if the temperature is not perfectly controlled, which is a major hurdle for distribution in remote areas or during emergencies. By enabling a stable, freeze-dried form of the anthrax vaccine, this technology reduces the need for a strict cold chain, making it easier to stockpile and transport life-saving medicine.

Real-world examples

• 1.BioThrax (anthrax vaccine)
• 2.Lyophilized vaccine stockpiles for public health defense